-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cardiac adipose tissue increases with type 2 diabetes in patients with heart vascular morbidity related
Diabetes, heart blood vessels
Recently, a research article published in Diabetes Obesity & Metabolism, an authoritative journal in the field of metabolic endocrine diseases, researchers put forward a hypothesis that treatment with liraglutide can reduce the amount of cardiac adipose tissue in patients with type 2 diabetes
The LIRAFLAME trial is a randomized placebo-controlled, double-blind, parallel clinical study
A total of 102 participants in the study were randomly assigned to the liraglutide group (n=51) or placebo group (n=51)
Liraglutide treatment can reduce cardiac adipose tissue after 26 weeks
.
Loss of cardiac adipose tissue is not related to weight loss, indicating that this is not a drug-specific effect
.
Original source:
Liraglutide Reduces Cardiac Adipose Tissue in the Type 2 Diabetes: A The Secondary Analysis of Randomized Placebo-Controlled Trial LIRAFLAME
in this message